PMA P990027S011

Device
BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM
Applicant
Technolas Perfect Vision GmbH
PMA number
P990027
Supplement
S011
Product code
LZS
Decision date
2009-05-01
Classification
Excimer Laser System
Generic name
Excimer laser system
Approval order statement
APPROVAL FOR THE DYNAMIC ROTATIONAL EYE TRACKER WITH IRIS RECOGNITION FOR USE WITH THE BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISIONCORRECTION. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISION CORRECTION AND IS INDICATED FOR:1) WAVEFRONT-GUIDED LASER ASSISTED IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS FOR THE REDUCTION ORELIMINATION OF MYOPIA WITH SPHERE UP TO -7.00 D AND CYLINDER UP TO -3.00 D AND MRSE < = 7.50 D ATTHE SPECTACLE PLANE:REDUCTION OR ELIMINATION OF MYOPIA (NEARSIGHTEDNESS) FROM -1.00 D TO -7.00 D WITH LESS THAN -3.00 D ASTIGMATISM;2) REDUCTION OR ELIMINATION OF MYOPIC ASTIGMATISM UP TO -12.00 D MRSE, WITH SPHERE BETWEEN > -7.00 D TO -10.99 D AND CYLINDER BETWEEN 0.00 AND < -3.00 D; AND 4) REDUCTION OR ELIMINATION OF LOW-TO-MODERATE NATURALLY OCCURRING HYPEROPIA UP TO +4.00 D MRSE, WITH SPHERE BETWEEN +1.00 D TO +4.00 D WITH OR WITHOUT REFRACTIVE ASTIGMATISM UP TO+2.00 D AT THE SPECTACLE PLANE.

Current openFDA PMA Record#

Device
BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM
Applicant
Technolas Perfect Vision GmbH
PMA number
P990027
Supplement
S011
Product code
LZS
Generic name
Excimer laser system
Decision date
2009-05-01
Decision code
APPR
Date received
2008-09-03
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Approval order statement
APPROVAL FOR THE DYNAMIC ROTATIONAL EYE TRACKER WITH IRIS RECOGNITION FOR USE WITH THE BAUSCH & LOMB TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISIONCORRECTION. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME TECHNOLAS 217Z ZYOPTIX LASER SYSTEM FOR PERSONALIZED VISION CORRECTION AND IS INDICATED FOR:1) WAVEFRONT-GUIDED LASER ASSISTED IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS FOR THE REDUCTION ORELIMINATION OF MYOPIA WITH SPHERE UP TO -7.00 D AND CYLINDER UP TO -3.00 D AND MRSE < = 7.50 D ATTHE SPECTACLE PLANE:REDUCTION OR ELIMINATION OF MYOPIA (NEARSIGHTEDNESS) FROM -1.00 D TO -7.00 D WITH LESS THAN -3.00 D ASTIGMATISM;2) REDUCTION OR ELIMINATION OF MYOPIC ASTIGMATISM UP TO -12.00 D MRSE, WITH SPHERE BETWEEN > -7.00 D TO -10.99 D AND CYLINDER BETWEEN 0.00 AND < -3.00 D; AND 4) REDUCTION OR ELIMINATION OF LOW-TO-MODERATE NATURALLY OCCURRING HYPEROPIA UP TO +4.00 D MRSE, WITH SPHERE BETWEEN +1.00 D TO +4.00 D WITH OR WITHOUT REFRACTIVE ASTIGMATISM UP TO+2.00 D AT THE SPECTACLE PLANE.